Dalotuzumab in chemorefractoryKRASexon 2 mutant colorectal cancer: Results from a randomised phase II/III trial-Reference-Cited by-同舟云学术

Dalotuzumab in chemorefractoryKRASexon 2 mutant colorectal cancer: Results from a randomised phase II/III trial

Published:2016-10-17 Issue:2 Volume:140 Page:431-439
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Sclafani Francesco¹,Kim Tae Y.²,Cunningham David¹,Kim Tae W.³,Tabernero Josep⁴,Schmoll Hans J.⁵,Roh Jae K.⁶,Kim Sun Y.⁷,Park Young S.⁸,Guren Tormod K.⁹,Hawkes Eliza¹,Clarke Stephen J.¹⁰,Ferry David¹¹,Frodin Jan-Erik¹²,Ayers Mark¹³,Nebozhyn Michael¹³,Peckitt Clare¹,Loboda Andrey¹³,Watkins David J.¹

Affiliation:

1. The Royal Marsden NHS Foundation Trust; London and Surrey; United Kingdom

2. Seoul National University College of Medicine; Seoul Korea

3. Department of Oncology; University of Ulsan College of Medicine, Asan Medical Center; Seoul Korea

4. Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; Barcelona Spain

5. Department of Internal Medicine; University Clinic Halle (Saale), Martin Luther University Halle-Wittenberg; Halle Germany

6. College of Medicine; Yonsey Cancer Center, Yonsey University; Seoul Korea

7. Center for Colorectal Cancer, National Cancer Center; Seoul Korea

8. Department of Medicine; Division of Hematology/Oncology; Samsung Medical Center; Seoul Korea

9. Department of Oncology and K.G. Jebsen Colorectal Cancer Research Centre; Oslo University Hospital; Oslo Norway

10. Concord Repatriation General Hospital; Concord Sydney Australia

11. New Cross Hospital; Wolverhamptom United Kingdom